Reduced transforming growth factor-β receptor II expression in hepatocellular carcinoma correlates with intrahepatic metastasis

Takao Mamiya, Ken Yamazaki, Yohei Masugi, Taisuke Mori, Kathryn Effendi, Wenlin Du, Taizo Hibi, Minoru Tanabe, Masakazu Ueda, Tadatoshi Takayama, Michiie Sakamoto

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Hepatocellular carcinoma (HCC) occurs mainly in the liver associated with chronic hepatitis and hepatic cirrhosis as a result of prolonged viral infection. Transforming growth factor-Β (TGF-Β) induces the fibrosis in hepatic cirrhosis, although it is also an inhibitor of hepatocyte proliferation. To understand the role of TGF-Β signaling in HCC progression, we analyzed gene expression in HCC cells in relation to TGF-Β signaling using a two-way clustering algorithm. By the analysis, five HCC cell lines were classified into two groups according to their metastatic capacity. TGF-Β receptor II (TGFBR2) was downregulated in metastatic cells, which did not show a response to TGF-Β. Immunohistochemistry demonstrated clear membrane distribution of TGFBR2 in noncancerous hepatocytes, whereas reduced TGFBR2 expression was observed in 34 of 136 HCCs. In clinical cases, reduced TGFBR2 expression correlated with larger tumor size (P0.001), poor differentiation (P0.001), portal vein invasion (P0.002), intrahepatic metastasis (IM) (P0.001), and shorter recurrence-free survival (P0.022). In conclusion, reduced TGFBR2 expression was associated with aggressive features of HCC such as IM, and may represent an immunohistochemical biomarker to detect aggressive HCC.

Original languageEnglish
Pages (from-to)1339-1345
Number of pages7
JournalLaboratory Investigation
Volume90
Issue number9
DOIs
Publication statusPublished - 2010

Fingerprint

Growth Factor Receptors
Transforming Growth Factors
Hepatocellular Carcinoma
Neoplasm Metastasis
Liver Cirrhosis
Hepatocytes
Virus Diseases
Chronic Hepatitis
Portal Vein
Cluster Analysis
Fibrosis
Down-Regulation
Biomarkers
Immunohistochemistry
Gene Expression
Recurrence
Cell Line
Membranes
Liver
Neoplasms

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Cell Biology
  • Molecular Biology
  • Medicine(all)

Cite this

Reduced transforming growth factor-β receptor II expression in hepatocellular carcinoma correlates with intrahepatic metastasis. / Mamiya, Takao; Yamazaki, Ken; Masugi, Yohei; Mori, Taisuke; Effendi, Kathryn; Du, Wenlin; Hibi, Taizo; Tanabe, Minoru; Ueda, Masakazu; Takayama, Tadatoshi; Sakamoto, Michiie.

In: Laboratory Investigation, Vol. 90, No. 9, 2010, p. 1339-1345.

Research output: Contribution to journalArticle

Mamiya, Takao ; Yamazaki, Ken ; Masugi, Yohei ; Mori, Taisuke ; Effendi, Kathryn ; Du, Wenlin ; Hibi, Taizo ; Tanabe, Minoru ; Ueda, Masakazu ; Takayama, Tadatoshi ; Sakamoto, Michiie. / Reduced transforming growth factor-β receptor II expression in hepatocellular carcinoma correlates with intrahepatic metastasis. In: Laboratory Investigation. 2010 ; Vol. 90, No. 9. pp. 1339-1345.
@article{1671470627bf4d2dad60c7f7dc76443b,
title = "Reduced transforming growth factor-β receptor II expression in hepatocellular carcinoma correlates with intrahepatic metastasis",
abstract = "Hepatocellular carcinoma (HCC) occurs mainly in the liver associated with chronic hepatitis and hepatic cirrhosis as a result of prolonged viral infection. Transforming growth factor-Β (TGF-Β) induces the fibrosis in hepatic cirrhosis, although it is also an inhibitor of hepatocyte proliferation. To understand the role of TGF-Β signaling in HCC progression, we analyzed gene expression in HCC cells in relation to TGF-Β signaling using a two-way clustering algorithm. By the analysis, five HCC cell lines were classified into two groups according to their metastatic capacity. TGF-Β receptor II (TGFBR2) was downregulated in metastatic cells, which did not show a response to TGF-Β. Immunohistochemistry demonstrated clear membrane distribution of TGFBR2 in noncancerous hepatocytes, whereas reduced TGFBR2 expression was observed in 34 of 136 HCCs. In clinical cases, reduced TGFBR2 expression correlated with larger tumor size (P0.001), poor differentiation (P0.001), portal vein invasion (P0.002), intrahepatic metastasis (IM) (P0.001), and shorter recurrence-free survival (P0.022). In conclusion, reduced TGFBR2 expression was associated with aggressive features of HCC such as IM, and may represent an immunohistochemical biomarker to detect aggressive HCC.",
author = "Takao Mamiya and Ken Yamazaki and Yohei Masugi and Taisuke Mori and Kathryn Effendi and Wenlin Du and Taizo Hibi and Minoru Tanabe and Masakazu Ueda and Tadatoshi Takayama and Michiie Sakamoto",
year = "2010",
doi = "10.1038/labinvest.2010.105",
language = "English",
volume = "90",
pages = "1339--1345",
journal = "Laboratory investigation; a journal of technical methods and pathology",
issn = "0023-6837",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Reduced transforming growth factor-β receptor II expression in hepatocellular carcinoma correlates with intrahepatic metastasis

AU - Mamiya, Takao

AU - Yamazaki, Ken

AU - Masugi, Yohei

AU - Mori, Taisuke

AU - Effendi, Kathryn

AU - Du, Wenlin

AU - Hibi, Taizo

AU - Tanabe, Minoru

AU - Ueda, Masakazu

AU - Takayama, Tadatoshi

AU - Sakamoto, Michiie

PY - 2010

Y1 - 2010

N2 - Hepatocellular carcinoma (HCC) occurs mainly in the liver associated with chronic hepatitis and hepatic cirrhosis as a result of prolonged viral infection. Transforming growth factor-Β (TGF-Β) induces the fibrosis in hepatic cirrhosis, although it is also an inhibitor of hepatocyte proliferation. To understand the role of TGF-Β signaling in HCC progression, we analyzed gene expression in HCC cells in relation to TGF-Β signaling using a two-way clustering algorithm. By the analysis, five HCC cell lines were classified into two groups according to their metastatic capacity. TGF-Β receptor II (TGFBR2) was downregulated in metastatic cells, which did not show a response to TGF-Β. Immunohistochemistry demonstrated clear membrane distribution of TGFBR2 in noncancerous hepatocytes, whereas reduced TGFBR2 expression was observed in 34 of 136 HCCs. In clinical cases, reduced TGFBR2 expression correlated with larger tumor size (P0.001), poor differentiation (P0.001), portal vein invasion (P0.002), intrahepatic metastasis (IM) (P0.001), and shorter recurrence-free survival (P0.022). In conclusion, reduced TGFBR2 expression was associated with aggressive features of HCC such as IM, and may represent an immunohistochemical biomarker to detect aggressive HCC.

AB - Hepatocellular carcinoma (HCC) occurs mainly in the liver associated with chronic hepatitis and hepatic cirrhosis as a result of prolonged viral infection. Transforming growth factor-Β (TGF-Β) induces the fibrosis in hepatic cirrhosis, although it is also an inhibitor of hepatocyte proliferation. To understand the role of TGF-Β signaling in HCC progression, we analyzed gene expression in HCC cells in relation to TGF-Β signaling using a two-way clustering algorithm. By the analysis, five HCC cell lines were classified into two groups according to their metastatic capacity. TGF-Β receptor II (TGFBR2) was downregulated in metastatic cells, which did not show a response to TGF-Β. Immunohistochemistry demonstrated clear membrane distribution of TGFBR2 in noncancerous hepatocytes, whereas reduced TGFBR2 expression was observed in 34 of 136 HCCs. In clinical cases, reduced TGFBR2 expression correlated with larger tumor size (P0.001), poor differentiation (P0.001), portal vein invasion (P0.002), intrahepatic metastasis (IM) (P0.001), and shorter recurrence-free survival (P0.022). In conclusion, reduced TGFBR2 expression was associated with aggressive features of HCC such as IM, and may represent an immunohistochemical biomarker to detect aggressive HCC.

UR - http://www.scopus.com/inward/record.url?scp=77956100350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956100350&partnerID=8YFLogxK

U2 - 10.1038/labinvest.2010.105

DO - 10.1038/labinvest.2010.105

M3 - Article

C2 - 20531292

AN - SCOPUS:77956100350

VL - 90

SP - 1339

EP - 1345

JO - Laboratory investigation; a journal of technical methods and pathology

JF - Laboratory investigation; a journal of technical methods and pathology

SN - 0023-6837

IS - 9

ER -